Skip to main content
Skip to content
Case File
sd-10-EFTA01392586Dept. of JusticeOther

EFTA Document EFTA01392586

GLOUS128 Patrick Gerschel SOF IV — Project Klein Exclusive deal Expected Glosing Date: June 2018 El Fund Secondary i Secondary K Single Asset Deal Seller type: Alternative funds Key investment data Transaction summary Invested Capital at dose E60-100m (US$80-120m) Number of companies 4 Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Business services / Healthcare services Use o

Date
Unknown
Source
Dept. of Justice
Reference
sd-10-EFTA01392586
Pages
1
Persons
0
Integrity
Loading PDF viewer...

Summary

GLOUS128 Patrick Gerschel SOF IV — Project Klein Exclusive deal Expected Glosing Date: June 2018 El Fund Secondary i Secondary K Single Asset Deal Seller type: Alternative funds Key investment data Transaction summary Invested Capital at dose E60-100m (US$80-120m) Number of companies 4 Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Business services / Healthcare services Use o

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
GLOUS128 Patrick Gerschel SOF IV — Project Klein Exclusive deal Expected Glosing Date: June 2018 El Fund Secondary i Secondary K Single Asset Deal Seller type: Alternative funds Key investment data Transaction summary Invested Capital at dose E60-100m (US$80-120m) Number of companies 4 Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Business services / Healthcare services Use of leverage No Average age at purchase 9 years Description - Motivated quality GP aiming to recapitalize and extend their 2007 mid- market pan-European fund while providing liquidity to LPs - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital Investment rationale / Glendower Team angle Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capita! to exploit market dislocations —':or discustun pitrposes«i4y. The invegrnimit presereed above I. s. rimt close-i. arid there is no guarantee irivestinent w3E cieviripliÅe or !Of fl‘ pag og I re givested portfc4m Mel g avaliatge or. &tiki furttwil due diligence, prove suitabki for :3OF nr This. slide idNould be med and ieviewc-d in conjunr.ition vrlth thelmponant Informationland "Important Perfoimance Infomiabon and • Notes to Investment Pedormance sections. Glendower Capital STRICTLY CONFIDENTIAL CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0097834 CONFIDENTIAL SDNY_GM_00244018 EFTA01392586

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.